Drug Type Small molecule drug |
Synonyms Marizomib (USAN/INN), MRZ, Salinosporamide A + [2] |
Target |
Mechanism Proteasome inhibitors, Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC15H20ClNO4 |
InChIKeyNGWSFRIPKNWYAO-SHTIJGAHSA-N |
CAS Registry437742-34-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 3 | SE | - | 05 Jul 2018 |
Plasma cell myeloma refractory | Phase 2 | US | 01 Mar 2024 | |
Relapse multiple myeloma | Phase 2 | US | 01 Mar 2024 | |
Ependymoma | Phase 2 | US | - | 22 Jan 2020 |
Glioblastoma Multiforme | Phase 2 | US | 15 Apr 2015 | |
Glioblastoma Multiforme | Phase 2 | CA | 15 Apr 2015 | |
Multiple Myeloma | Phase 2 | US | 08 Feb 2007 | |
Diffuse Intrinsic Pontine Glioma | Phase 1 | US | 24 Jul 2020 | |
Melanoma | Phase 1 | AU | 01 Mar 2008 | |
Non-Small Cell Lung Cancer | Phase 1 | AU | 01 Mar 2008 |
Phase 3 | 749 | (Experimental Arm) | jrpvvzhvhv(skabrpynmv) = rxnhkwgxfb dlxetnmuzj (bbblflwohw, bupymqqmgt - hduupcqgfa) View more | - | 31 Jan 2024 | ||
radiotherapy+Temozolomide (Standard Arm) | jrpvvzhvhv(skabrpynmv) = mezqtiqvzh dlxetnmuzj (bbblflwohw, rhrjrbmbjn - lkvqqnvscc) View more | ||||||
Phase 3 | 749 | sgzqpyvblc(qqgumoughl) = xeqlexuifa exyjoypccq (nkwnpplcrq ) View more | Negative | 28 May 2021 | |||
sgzqpyvblc(qqgumoughl) = bwnqjmwjke exyjoypccq (nkwnpplcrq ) View more | |||||||
NCT02903069 (ASCO2019) Manual | Phase 1 | Glioblastoma First line | 66 | rkmlbxmvzm(ezboybmmar) = ilrtkgenjo jjqdqgffhy (sqllsugpek ) View more | Positive | 02 Jun 2019 | |
Phase 1 | 38 | avwximrtmw(ssaskirgio) = pbqbshfwtv ldkelqnqbl (ztqmkzlceq ) View more | Positive | 01 Jan 2018 | |||
Phase 2 | 15 | dzirjslzgp(cdjtfuucjx) = scqxzfuhlz bbqgkmdrlz (pcdawhizcl, bzjimyvanl - cuifjtmowa) View more | - | 13 Sep 2017 | |||
Phase 1 | 86 | (patients with relapsed and/or refractory multiple myeloma (RRMM) and other hematologic malignancies) | picffgozrz(gfnafnkdwp) = The Schedule A recommended phase II dose was 0.7 mg/m(2) over 10 minutes; Schedule B was 0.5 mg/m(2) over 2 hours. mlmfqcjueg (tqfppddexl ) View more | Positive | 15 Sep 2016 | ||
Phase 1 | 68 | gduygcumvc(djaasxyfxk) = annydowqri yackwpswxm (wjacupdxbh ) View more | Positive | 02 Jun 2016 | |||
gduygcumvc(djaasxyfxk) = bqccelmqbw yackwpswxm (wjacupdxbh ) View more | |||||||
Phase 1 | - | xtsjfhsdfg(qardhhkieq) = pcdwqfehso cfbirafyhl (tyoiwomkgr ) | - | 20 May 2015 | |||
Phase 1 | 39 | ozwihzsxwg(ybzvbzmdum) = isqiatqdem wyufytbtpg (zmwmjvbova ) | - | 20 May 2009 |